NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS

1.	SUMMARY OF ACCOUNTING POLICIES
2.	CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS
3.	FINANCIAL RISK MANAGEMENT
4.	BUSINESS COMBINATIONS
5.	SEGMENT INFORMATION
6.	PROPERTY AND EQUIPMENT
7.	INVESTMENT PROPERTY
8.	INTANGIBLE ASSETS
9.	FINANCIAL INSTRUMENTS
10.	INVESTMENT IN ASSOCIATES
11.	INVESTMENT IN SUBSIDIARIES
12.	DEFERRED INCOME TAX
13.	INVENTORY
14.	ISSUED SHARE CAPITAL
15.	SHARE PREMIUM
16.	NON-CONTROLLING INTEREST
17.	PROVISIONS
18.	POST-EMPLOYMENT MEDICAL OBLIGATIONS
19.	ACCRUAL FOR STRAIGHT-LINING OF LEASES
20.	EMPLOYMENT BENEFIT LIABILITY
21.	REVENUE
22.	COST OF PHARMACEUTICAL PRODUCTS
23.	PROFIT BEFORE TAXATION
24.	NET FINANCE COSTS
25.	INCOME TAX EXPENSE
26.	EARNINGS PER SHARE
27.	CASH GENERATED FROM OPERATIONS
28.	TAXATION PAID
29.	DIVIDENDS
30.	SHARE-BASED PAYMENTS
31.	CONTINGENCIES, COMMITMENTS AND GUARANTEES
32.	RELATED PARTY TRANSACTIONS
33.	PENSIONS AND OTHER RETIREMENT OBLIGATIONS
34.	CONTINGENT CONSIDERATION
35.	CONDITIONAL FINANCIAL OBLIGATION
36.	CONDITIONAL PUT OPTION RESERVE
37.	DEFERRED PAYMENT
38.	SUBSEQUENT EVENTS
39.	RESTATEMENT OF JUNE 2016 RESULTS